DFIB Cardiac Science (MM)

Cardiac Science Announces Date of 2004 Third Quarter and Nine-Month Results Release and Conference Call IRVINE, Calif., Oct. 21 /PRNewswire/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a leading manufacturer of life-saving automated public access defibrillators, today announced plans to release its results for the third quarter and nine-months ended September 30, 2004, at 1:30 a.m. EDT on Wednesday, October 27, 2004. That same day, management will host a conference call to be broadcast live on the Internet at 11:30 a.m. EDT. Management encourages shareholders and other interested parties to listen to the live webcast by going to the company's website at http://www.cardiacscience.com/. Web participants should go to the company's website at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. The online archive of the call will be available immediately following the conference call. About Cardiac Science Cardiac Science develops, manufactures and markets a complete line of Powerheart(R) brand, automated public access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The company makes the Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit http://www.cardiacscience.com/ or call 1.949.797.3800. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to the achievement of future revenue growth and the lowering of the company's breakeven revenue level by the third quarter. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2003, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission. For more information, please contact: Investors, Matt Clawson of Allen & Caron Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or Roderick de Greef, EVP and CFO of Cardiac Science, Inc., +1-949-797-3800, . DATASOURCE: Cardiac Science, Inc. CONTACT: Investors, Matt Clawson of Allen & Caron Inc, +1-949-474-4300, , for Cardiac Science; or Roderick de Greef, EVP and CFO of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright